Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| NovoCure LtdNVCR · Entity 4494 | Chief Operating Officer | March 03, 2026 | March 05, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
NovoCure Ltd
Report date March 03, 2026 · Filed March 05, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Ordinary SharesSEC Table I · non-derivative | Direct | 121,455 |
Reported balance
After 2026-03-03 transaction · row 1
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 1 · 2026-03-03 · Grant · Acquired 45,112 · Balance 121,455 F1: Represents restricted share units that are scheduled to vest in equal parts on the first, second and third anniversary of the grant date, subject to the reporting person's continued employment through such dates. |
| Ordinary SharesSEC Table I · non-derivative | Direct | 116,078 |
Reported balance
After 2026-03-04 transaction · row 2
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 2 · 2026-03-04 · Sale · Disposed 5,377 · Balance 116,078 F2: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of Restricted Stock Units. This sale is mandated by the issuer's award agreement under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person. F3: This transaction was executed in multiple trades at prices ranging from $13.21 USD to $13.445 USD; the price reported above reflects the weighted average sale price. |
| Ordinary SharesSEC Table I · non-derivative | Direct | 72,832 |
Reported balance
After 2026-03-05 transaction · row 3
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 3 · 2026-03-05 · Sale · Disposed 43,246 · Balance 72,832 F4: This transaction was executed in multiple trades at prices ranging from $13.74 USD to $14.07 USD; the price reported above reflects the weighted average sale price. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $13.30 · Expires 2036-03-03 | Direct | 7,518 |
Reported balance
After 2026-03-03 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2026-03-03 · Grant · Acquired 7,518 · Balance 7,518 F5: Options to buy ordinary shares that are scheduled to vest in equal parts on the first, second, third and fourth anniversary of the grant date, subject to the reporting person's continued employment through such date. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $13.30 · Expires 2036-03-03 | Direct | 66,006 |
Reported balance
After 2026-03-03 transaction · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · 2026-03-03 · Grant · Acquired 58,488 · Balance 66,006 F5: Options to buy ordinary shares that are scheduled to vest in equal parts on the first, second, third and fourth anniversary of the grant date, subject to the reporting person's continued employment through such date. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents restricted share units that are scheduled to vest in equal parts on the first, second and third anniversary of the grant date, subject to the reporting person's continued employment through such dates.
F2: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of Restricted Stock Units. This sale is mandated by the issuer's award agreement under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person.
F3: This transaction was executed in multiple trades at prices ranging from $13.21 USD to $13.445 USD; the price reported above reflects the weighted average sale price.
F4: This transaction was executed in multiple trades at prices ranging from $13.74 USD to $14.07 USD; the price reported above reflects the weighted average sale price.
F5: Options to buy ordinary shares that are scheduled to vest in equal parts on the first, second, third and fourth anniversary of the grant date, subject to the reporting person's continued employment through such date.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| March 05, 2026 Filed Mar 5, 2026 16:31 UTC | NovoCure Ltd NVCR · Entity 4494 | SaleOrdinary Shares | 43,246 | $13.77 | $595,670.40 |
DisclosureSEC source: 0002039078-26-000005 · primarydocument.xml · nonDerivative · entry 3 Paravasthu Mukund · CIK 0002039078 · Chief Operating Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 72,832 F4 · price: This transaction was executed in multiple trades at prices ranging from $13.74 USD to $14.07 USD; the price reported above reflects the weighted average sale price. Read SEC document |
| March 04, 2026 Filed Mar 5, 2026 16:31 UTC | NovoCure Ltd NVCR · Entity 4494 | SaleOrdinary Shares | 5,377 | $13.31 | $71,543.14 |
DisclosureSEC source: 0002039078-26-000005 · primarydocument.xml · nonDerivative · entry 2 Paravasthu Mukund · CIK 0002039078 · Chief Operating Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 116,078 F2 · shares: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of Restricted Stock Units. This sale is mandated by the issuer's award agreement under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person. F3 · price: This transaction was executed in multiple trades at prices ranging from $13.21 USD to $13.445 USD; the price reported above reflects the weighted average sale price. Read SEC document |
| March 03, 2026 Filed Mar 5, 2026 16:31 UTC | NovoCure Ltd NVCR · Entity 4494 | GrantStock Option (Right to Buy) · Derivative | 58,488 | $0.00 Strike: $13.30 | $0.00 |
DisclosureSEC source: 0002039078-26-000005 · primarydocument.xml · derivative · entry 5 Paravasthu Mukund · CIK 0002039078 · Chief Operating Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 66,006 Underlying: Ordinary Shares · 58,488 shares Expires 2036-03-03 F5 · derivative.exercise_date: Options to buy ordinary shares that are scheduled to vest in equal parts on the first, second, third and fourth anniversary of the grant date, subject to the reporting person's continued employment through such date. Read SEC document |
| March 03, 2026 Filed Mar 5, 2026 16:31 UTC | NovoCure Ltd NVCR · Entity 4494 | GrantStock Option (Right to Buy) · Derivative | 7,518 | $0.00 Strike: $13.30 | $0.00 |
DisclosureSEC source: 0002039078-26-000005 · primarydocument.xml · derivative · entry 4 Paravasthu Mukund · CIK 0002039078 · Chief Operating Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 7,518 Underlying: Ordinary Shares · 7,518 shares Expires 2036-03-03 F5 · derivative.exercise_date: Options to buy ordinary shares that are scheduled to vest in equal parts on the first, second, third and fourth anniversary of the grant date, subject to the reporting person's continued employment through such date. Read SEC document |
| March 03, 2026 Filed Mar 5, 2026 16:31 UTC | NovoCure Ltd NVCR · Entity 4494 | GrantOrdinary Shares | 45,112 | $0.00 | $0.00 |
DisclosureSEC source: 0002039078-26-000005 · primarydocument.xml · nonDerivative · entry 1 Paravasthu Mukund · CIK 0002039078 · Chief Operating Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 121,455 F1 · security: Represents restricted share units that are scheduled to vest in equal parts on the first, second and third anniversary of the grant date, subject to the reporting person's continued employment through such dates. Read SEC document |
| March 02, 2026 Filed Mar 3, 2026 16:10 UTC | NovoCure Ltd NVCR · Entity 4494 | SaleOrdinary Shares | 408 | $13.49 | $5,505.14 |
DisclosureSEC source: 0002039078-26-000004 · primarydocument.xml · nonDerivative · entry 2 Paravasthu Mukund · CIK 0002039078 · Chief Operating Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 76,343 F1 · shares: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of Restricted Stock Units. This sale is mandated by the issuer's award agreement under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person. F3 · price: This transaction was executed in multiple trades at prices ranging from $13.3126 USD to $13.70 USD; the price reported above reflects the weighted average sale price. Read SEC document |
| February 27, 2026 Filed Mar 3, 2026 16:10 UTC | NovoCure Ltd NVCR · Entity 4494 | SaleOrdinary Shares | 1,555 | $13.66 | $21,247.21 |
DisclosureSEC source: 0002039078-26-000004 · primarydocument.xml · nonDerivative · entry 1 Paravasthu Mukund · CIK 0002039078 · Chief Operating Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 76,751 F1 · shares: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of Restricted Stock Units. This sale is mandated by the issuer's award agreement under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person. F2 · price: This transaction was executed in multiple trades at prices ranging from $13.45 USD to $13.97 USD; the price reported above reflects the weighted average sale price. Read SEC document |
| January 11, 2026 Filed Jan 12, 2026 17:30 UTC | NovoCure Ltd NVCR · Entity 4494 | Tax withholdingOrdinary Shares | 2,133 | $14.35 | $30,608.55 |
DisclosureSEC source: 0002039078-26-000002 · primarydocument.xml · nonDerivative · entry 1 Paravasthu Mukund · CIK 0002039078 · Chief Operating Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 78,306 F1 · shares: Represents the number of shares required to be withheld by the issuer to cover tax withholding obligations in connection with the vesting of Restricted Stock Units. This transaction is not discretionary and approved as required pursuant to Rules 16b-3(e) and 16b-3(d)(1). Read SEC document |
| November 04, 2025 Filed Nov 4, 2025 16:09 UTC | NovoCure Ltd NVCR · Entity 4494 | Tax withholdingOrdinary Shares | 2,949 | $12.23 | $36,066.27 |
DisclosureSEC source: 0002039078-25-000004 · primarydocument.xml · nonDerivative · entry 2 Paravasthu Mukund · CIK 0002039078 · Chief Operating Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 80,439 F1 · shares: Represents the number of shares required to be withheld by the issuer to cover tax withholding obligations in connection with the vesting of Restricted Stock Units. This transaction is not discretionary and approved as required pursuant to Rules 16b-3(e) and 16b-3(d)(1). Read SEC document |
| November 01, 2025 Filed Nov 4, 2025 16:09 UTC | NovoCure Ltd NVCR · Entity 4494 | Tax withholdingOrdinary Shares | 168 | $12.81 | $2,152.08 |
DisclosureSEC source: 0002039078-25-000004 · primarydocument.xml · nonDerivative · entry 1 Paravasthu Mukund · CIK 0002039078 · Chief Operating Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 83,388 F1 · shares: Represents the number of shares required to be withheld by the issuer to cover tax withholding obligations in connection with the vesting of Restricted Stock Units. This transaction is not discretionary and approved as required pursuant to Rules 16b-3(e) and 16b-3(d)(1). Read SEC document |
| May 03, 2025 Filed May 5, 2025 16:17 UTC | NovoCure Ltd NVCR · Entity 4494 | SaleOrdinary Shares | 592 | $17.91 | $10,604.20 |
DisclosureSEC source: 0001562180-25-003589 · primarydocument.xml · nonDerivative · entry 1 Paravasthu Mukund · CIK 0002039078 · Chief Operating Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 83,556 F1 · shares: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of Restricted Stock Units. This sale is mandated by the issuer's award agreement under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person. F2 · price: This transaction was executed in multiple trades at prices ranging from $17.8550 USD to $17.9498 USD; the price reported above reflects the weighted average sale price. Read SEC document |
| March 04, 2025 Filed Mar 6, 2025 16:40 UTC | NovoCure Ltd NVCR · Entity 4494 | GrantStock Options (Right to buy) · Derivative | 81,499 | $18.19 Strike: $18.19 | $1,482,466.81 |
DisclosureSEC source: 0001562180-25-002157 · primarydocument.xml · derivative · entry 2 Paravasthu Mukund · CIK 0002039078 · Chief Operating Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 81,499 Underlying: Ordinary Shares · 81,499 shares Expires 2035-03-03 F2 · derivative.exercise_date: Options to buy 81,499 ordinary shares will vest in equal installments on each of March 4, 2026, 2027, 2028 and 2029, subject to the reporting person's continued employment through such dates. Read SEC document |
| March 04, 2025 Filed Mar 6, 2025 16:40 UTC | NovoCure Ltd NVCR · Entity 4494 | GrantOrdinary Shares | 54,975 | $18.19 | $999,995.25 |
DisclosureSEC source: 0001562180-25-002157 · primarydocument.xml · nonDerivative · entry 1 Paravasthu Mukund · CIK 0002039078 · Chief Operating Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 84,148 F1 · shares: Represents restricted share units that are scheduled to vest in equal installments on March 4, 2026, 2027 and 2028, subject to the reporting person's continued employment through such dates. Read SEC document |
| March 03, 2025 Filed Mar 4, 2025 16:16 UTC | NovoCure Ltd NVCR · Entity 4494 | SaleOrdinary Shares | 250 | $18.54 | $4,634.08 |
DisclosureSEC source: 0001562180-25-001974 · primarydocument.xml · nonDerivative · entry 1 Paravasthu Mukund · CIK 0002039078 · Chief Operating Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 29,173 F1 · shares: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of Restricted Stock Units. This sale is mandated by the issuer's award agreement under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person. F2 · price: On the transaction date, the reporting person sold 250 shares in multiple trades at prices ranging from $18.02 to $18.9918. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide to the Staff, the issuer for any security holder of the issuer, upon request, full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| February 28, 2025 Filed Mar 3, 2025 21:26 UTC Amendment | NovoCure Ltd NVCR · Entity 4494 | SaleOrdinary Shares | 368 | $18.28 | $6,728.62 |
DisclosureSEC source: 0001562180-25-001912 · primarydocument.xml · nonDerivative · entry 3 Paravasthu Mukund · CIK 0002039078 · Chief Operating Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 29,423 F1 · shares: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of Restricted Stock Units. This sale is mandated by the issuer's award agreement under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person. F4 · price: On February 28, 2025, the reporting person sold 368 shares in multiple trades at prices ranging from $18.175 to $18.765. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide to the Staff, the issuer for any security holder of the issuer, upon request, full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| February 28, 2025 Filed Mar 3, 2025 16:26 UTC | NovoCure Ltd NVCR · Entity 4494 | SaleOrdinary Shares | 368 | $18.28 | $6,728.62 |
DisclosureSEC source: 0001562180-25-001831 · primarydocument.xml · nonDerivative · entry 3 Paravasthu Mukund · CIK 0002039078 · Chief Operating Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 29,423 F3 · price: On February 28, 2025, the reporting person sold 368 shares in multiple trades at prices ranging from $18.175 to $18.765. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide to the Staff, the issuer for any security holder of the issuer, upon request, full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| February 27, 2025 Filed Mar 3, 2025 21:26 UTC Amendment | NovoCure Ltd NVCR · Entity 4494 | SaleOrdinary Shares | 267 | $20.55 | $5,486.58 |
DisclosureSEC source: 0001562180-25-001912 · primarydocument.xml · nonDerivative · entry 2 Paravasthu Mukund · CIK 0002039078 · Chief Operating Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 29,791 F1 · shares: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of Restricted Stock Units. This sale is mandated by the issuer's award agreement under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person. F3 · price: On February 27, 2025, the reporting person sold 267 shares in multiple trades at prices ranging from $20.41 to $20.85. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide to the Staff, the issuer for any security holder of the issuer, upon request, full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| February 27, 2025 Filed Mar 3, 2025 21:26 UTC Amendment | NovoCure Ltd NVCR · Entity 4494 | SaleOrdinary Shares | 1,379 | $19.92 | $27,472.30 |
DisclosureSEC source: 0001562180-25-001912 · primarydocument.xml · nonDerivative · entry 1 Paravasthu Mukund · CIK 0002039078 · Chief Operating Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 30,058 F1 · shares: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of Restricted Stock Units. This sale is mandated by the issuer's award agreement under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person. F2 · price: On February 27, 2025, the reporting person sold 1,379 shares in multiple trades at prices ranging from $19.41 to $20.4033. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide to the Staff, the issuer for any security holder of the issuer, upon request, full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| February 27, 2025 Filed Mar 3, 2025 16:26 UTC | NovoCure Ltd NVCR · Entity 4494 | SaleOrdinary Shares | 267 | $20.55 | $5,486.58 |
DisclosureSEC source: 0001562180-25-001831 · primarydocument.xml · nonDerivative · entry 2 Paravasthu Mukund · CIK 0002039078 · Chief Operating Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 29,791 F2 · price: On February 27, 2025, the reporting person sold 267 shares in multiple trades at prices ranging from $20.41 to $20.85. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide to the Staff, the issuer for any security holder of the issuer, upon request, full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| February 27, 2025 Filed Mar 3, 2025 16:26 UTC | NovoCure Ltd NVCR · Entity 4494 | SaleOrdinary Shares | 1,379 | $19.92 | $27,472.30 |
DisclosureSEC source: 0001562180-25-001831 · primarydocument.xml · nonDerivative · entry 1 Paravasthu Mukund · CIK 0002039078 · Chief Operating Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 30,058 F1 · price: On February 27, 2025, the reporting person sold 1,379 shares in multiple trades at prices ranging from $19.41 to $20.4033. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide to the Staff, the issuer for any security holder of the issuer, upon request, full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| January 11, 2025 Filed Jan 15, 2025 16:23 UTC | NovoCure Ltd NVCR · Entity 4494 | SaleOrdinary Shares | 2,160 | $26.81 | $57,906.14 |
DisclosureSEC source: 0001562180-25-000375 · primarydocument.xml · nonDerivative · entry 1 Paravasthu Mukund · CIK 0002039078 · Chief Operating Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 31,437 F1 · shares: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of Restricted Stock Units. This sale is mandated by the issuer's award agreement under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person. F2 · price: This transaction was executed in multiple trades at prices ranging from $26.44 USD to $27.185 USD; the price reported above reflects the weighted average sale price. Read SEC document |
| November 04, 2024 Filed Nov 6, 2024 16:27 UTC | NovoCure Ltd NVCR · Entity 4494 | GrantStock Option (Right to Buy) · Derivative | 45,620 | $16.59 Strike: $16.59 | $756,835.80 |
DisclosureSEC source: 0001562180-24-007567 · primarydocument.xml · derivative · entry 3 Paravasthu Mukund · CIK 0002039078 · Chief Operating Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 45,620 Underlying: Ordinary Shares · 45,620 shares Expires 2034-11-03 F3 · derivative.exercise_date: Options to buy 45,620 ordinary shares will vest in equal installments on each of November 4, 2025, 2026, 2027 and 2028, subject to the reporting person's continued employment through such dates. Read SEC document |
| November 04, 2024 Filed Nov 6, 2024 16:27 UTC | NovoCure Ltd NVCR · Entity 4494 | GrantOrdinary Shares | 30,138 | $0.00 | $0.00 |
DisclosureSEC source: 0001562180-24-007567 · primarydocument.xml · nonDerivative · entry 2 Paravasthu Mukund · CIK 0002039078 · Chief Operating Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 33,597 F2 · shares: Represents restricted share units that are scheduled to vest in equal parts on November 4, 2025, 2026 and 2027, subject to the reporting person's continued employment through such dates. Read SEC document |
| November 02, 2024 Filed Nov 6, 2024 16:27 UTC | NovoCure Ltd NVCR · Entity 4494 | SaleOrdinary Shares | 44 | $16.69 | $734.18 |
DisclosureSEC source: 0001562180-24-007567 · primarydocument.xml · nonDerivative · entry 1 Paravasthu Mukund · CIK 0002039078 · Chief Operating Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 3,459 F1 · shares: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of Restricted Stock Units. This sale is mandated by the issuer's award agreement under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person. Read SEC document |
| November 01, 2024 Filed Nov 4, 2024 16:32 UTC | NovoCure Ltd NVCR · Entity 4494 | SaleOrdinary Shares | 160 | $15.88 | $2,540.42 |
DisclosureSEC source: 0001562180-24-007515 · primarydocument.xml · nonDerivative · entry 1 Paravasthu Mukund · CIK 0002039078 · Chief Operating Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 3,503 F1 · shares: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of Restricted Stock Units. This sale is mandated by the issuer's award agreement under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person. F2 · price: This transaction was executed in multiple trades at prices ranging from $15.80 USD to $15.94 USD; the price reported above reflects the weighted average sale price. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.